Matinas BioPharma Holdings, Inc.MTNB
Price (close)
$0.18
Market cap
$2.6M
P/E
—
Revenue (TTM)
—
Net income
-$6.7M
Dividend yield
—
1-year total return
-90.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Matinas BioPharma Holdings, Inc. does.
delivering groundbreaking therapies using our lipid nanocrystal (“LNC”) platform delivery technology (the “LNC Platform”).
lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made
oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. Following the
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $158,333 | $33,000 | $3.2M | $1.1M | — | — |
| Net income | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Free cash flow | -$17.4M | -$15.5M | -$20.0M | -$15.5M | — | — |
More on MTNB.
- Matinas BioPharma Holdings, Inc. summary
- Matinas BioPharma Holdings, Inc. financial statements
- Matinas BioPharma Holdings, Inc. key metrics
- Matinas BioPharma Holdings, Inc. health scores and style box
- Matinas BioPharma Holdings, Inc. earnings
- Matinas BioPharma Holdings, Inc. dividends
- Matinas BioPharma Holdings, Inc. valuation
- Matinas BioPharma Holdings, Inc. ownership and insiders
- Matinas BioPharma Holdings, Inc. peers
Figures from Matinas BioPharma Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.